Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GSK3A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GSK3A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GSK3A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GSK3A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GSK3A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GSK3A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004217635 | Thyroid | ATC | regulation of protein catabolic process | 239/6293 | 391/18723 | 2.63e-29 | 1.85e-26 | 239 |
GO:007259429 | Thyroid | ATC | establishment of protein localization to organelle | 247/6293 | 422/18723 | 2.88e-26 | 1.40e-23 | 247 |
GO:190336235 | Thyroid | ATC | regulation of cellular protein catabolic process | 168/6293 | 255/18723 | 3.50e-26 | 1.58e-23 | 168 |
GO:003238632 | Thyroid | ATC | regulation of intracellular transport | 203/6293 | 337/18723 | 6.16e-24 | 1.85e-21 | 203 |
GO:190305035 | Thyroid | ATC | regulation of proteolysis involved in cellular protein catabolic process | 146/6293 | 221/18723 | 4.18e-23 | 1.20e-20 | 146 |
GO:002241124 | Thyroid | ATC | cellular component disassembly | 248/6293 | 443/18723 | 1.34e-22 | 3.69e-20 | 248 |
GO:006113633 | Thyroid | ATC | regulation of proteasomal protein catabolic process | 128/6293 | 187/18723 | 1.63e-22 | 4.30e-20 | 128 |
GO:2000058210 | Thyroid | ATC | regulation of ubiquitin-dependent protein catabolic process | 116/6293 | 164/18723 | 2.15e-22 | 5.43e-20 | 116 |
GO:0032434210 | Thyroid | ATC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 100/6293 | 134/18723 | 2.41e-22 | 5.86e-20 | 100 |
GO:0045732210 | Thyroid | ATC | positive regulation of protein catabolic process | 148/6293 | 231/18723 | 1.93e-21 | 4.36e-19 | 148 |
GO:003315726 | Thyroid | ATC | regulation of intracellular protein transport | 147/6293 | 229/18723 | 2.01e-21 | 4.38e-19 | 147 |
GO:190336434 | Thyroid | ATC | positive regulation of cellular protein catabolic process | 109/6293 | 155/18723 | 8.26e-21 | 1.49e-18 | 109 |
GO:190332034 | Thyroid | ATC | regulation of protein modification by small protein conjugation or removal | 152/6293 | 242/18723 | 9.76e-21 | 1.71e-18 | 152 |
GO:1903829210 | Thyroid | ATC | positive regulation of cellular protein localization | 167/6293 | 276/18723 | 3.32e-20 | 5.38e-18 | 167 |
GO:003238825 | Thyroid | ATC | positive regulation of intracellular transport | 131/6293 | 202/18723 | 8.20e-20 | 1.24e-17 | 131 |
GO:190180027 | Thyroid | ATC | positive regulation of proteasomal protein catabolic process | 85/6293 | 114/18723 | 3.70e-19 | 5.20e-17 | 85 |
GO:003139634 | Thyroid | ATC | regulation of protein ubiquitination | 132/6293 | 210/18723 | 3.13e-18 | 3.98e-16 | 132 |
GO:000660533 | Thyroid | ATC | protein targeting | 180/6293 | 314/18723 | 3.54e-18 | 4.39e-16 | 180 |
GO:000609134 | Thyroid | ATC | generation of precursor metabolites and energy | 256/6293 | 490/18723 | 6.55e-18 | 7.69e-16 | 256 |
GO:009031624 | Thyroid | ATC | positive regulation of intracellular protein transport | 107/6293 | 160/18723 | 6.82e-18 | 7.84e-16 | 107 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GSK3A | SNV | Missense_Mutation | | c.430N>G | p.Leu144Val | p.L144V | P49840 | protein_coding | tolerated(0.34) | benign(0.005) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
GSK3A | SNV | Missense_Mutation | rs750207489 | c.757N>A | p.Asp253Asn | p.D253N | P49840 | protein_coding | tolerated(0.54) | benign(0.286) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
GSK3A | SNV | Missense_Mutation | | c.710N>T | p.Ser237Phe | p.S237F | P49840 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
GSK3A | SNV | Missense_Mutation | | c.758N>G | p.Asp253Gly | p.D253G | P49840 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD |
GSK3A | insertion | Frame_Shift_Ins | novel | c.1322_1323insTACAGGCGTGAAC | p.Pro442ThrfsTer26 | p.P442Tfs*26 | P49840 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
GSK3A | insertion | Frame_Shift_Ins | novel | c.1320_1321insCCGCTTGGCCTCCTAAAGTGTTGGG | p.Ile441ProfsTer31 | p.I441Pfs*31 | P49840 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
GSK3A | SNV | Missense_Mutation | novel | c.787N>A | p.Asp263Asn | p.D263N | P49840 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSK3A | SNV | Missense_Mutation | novel | c.616G>C | p.Ala206Pro | p.A206P | P49840 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
GSK3A | SNV | Missense_Mutation | novel | c.288C>A | p.Asp96Glu | p.D96E | P49840 | protein_coding | tolerated(0.21) | benign(0.056) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
GSK3A | SNV | Missense_Mutation | | c.1264N>G | p.Leu422Val | p.L422V | P49840 | protein_coding | deleterious(0) | benign(0.377) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | Thiadiazolidindione derivative 2 | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | PMID27828716-Compound-BIO-acetoxime | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | CHIR-99021 | CHIR-99021 | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | inhibitor | 249565696 | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | PHA-767491 | CHEMBL225519 | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | AR-A014418 | CHEMBL259850 | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | KENPAULLONE | KENPAULLONE | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | PMID27828716-Compound-17 | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | Maleimides derivative 3 | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | Indazole derivative 6 | | |